Not all patients with CLL have to have therapy. In spite of all the latest innovations, the iwCLL however endorses watchful observation for individuals with asymptomatic disorder.86 This advice relies on at the least two randomized trials evaluating observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).